Ripretinib, sold under the brand name Qinlock, is a medication for the treatment of adults with advanced gastrointestinal stromal tumor, a type of tumor that originates in the gastrointestinal tract. It is taken by mouth. Ripretinib is a targeted kinase inhibitor designed as a switch control inhibitor that binds to and stabilizes inactive conformations of KIT and PDGFRA kinases, suppressing signaling from a broad spectrum of primary and resistance-associated kinase mutants. The oral formulation supports once daily dosing. Pharmacologically, ripretinib achieves systemic exposure consistent with inhibition of oncogenic KIT and PDGFRA signaling and is metabolized primarily via hepatic cytochrome P450 pathways including CYP3A enzymes, with metabolites that contribute to overall activity. Safety considerations include monitoring for class-related adverse effects and potential drug interactions with strong CYP3A inhibitors or inducers.
Parent: Ripretinib
Parent: Ripretinib
Parent: Ripretinib
Parent: Ripretinib
Parent: Ripretinib
Typical quality specifications for ripretinib drug substance and finished product control assay, related compounds and impurities to meet regulatory standards. Representative analytical acceptance criteria include assay 98.0 to 102.0 percent of labeled amount. Identified related compounds or degradants are commonly limited to 0.5 percent or less individually. Unidentified or unspecified impurities are typically controlled at 0.1 percent or lower individually. Total impurities are commonly limited to 1.0 percent or less. Additional controls include limits for residual solvents in line with ICH Q3C and elemental impurities consistent with applicable pharmacopeial limits, for example elemental impurities often set at single-digit parts per million where required.
Ripretinib is used to treat adults with advanced gastrointestinal stromal tumor who have received prior treatment with kinase inhibitors and is intended to inhibit KIT and PDGFRA-driven tumor growth.
The cost of ripretinib varies by country, pharmacy, insurance coverage and patient assistance options. For an exact retail price and coverage details contact local pharmacies, insurance providers or the manufacturer patient support program.
Yes. Ripretinib is a type of tyrosine kinase inhibitor that targets KIT and PDGFRA and is designed to inhibit a range of activating and resistance mutations.
Ripretinib received regulatory approval for the treatment of advanced gastrointestinal stromal tumor following clinical review by relevant health authorities. For the specific approval date in your country consult the prescribing information or the regulatory agency website.
